Please select the option that best describes you:
What are your top takeaways in GU Cancers from ASTRO 2024?
Answer from: Radiation Oncologist at Academic Institution
The Presidential Symposium was outstanding. Dr. Brandon Mahal’s presentation hit on a top priority for the field, in my view: how do we improve/accelerate the implementation of advances like focal microboost for prostate cancer? RCT evidence of benefit to dose escalation is rare in rad onc. ...
Sign in or Register to read more
Answer from: Radiation Oncologist at Academic Institution
PARTIQoL: This phase III trial randomized 450 men with low- or intermediate-risk prostate cancer to receive definitive external beam radiation therapy with either photons (control arm) or protons (experimental arm). The radiation dose/fractionation was either conventional fractionation or modera...
Answer from: Radiation Oncologist at Academic Institution
@Jason Efstathiou, MD, PhD presented the results of the PARTIQoL trial, a Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Localized Prostate Cancer. Patients with intermediate- or low-risk prostate cancer were randomized to PBT or IMRT, without hormonal therapy, stratified for i...
Answer from: Radiation Oncologist at Academic Institution
The PARTIQoL trial can help reassure patients that they need not travel long distances to receive proton therapy for their localized prostate cancer.
(PL 01 – Plenary Session) LBA01 - Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): Phase III Randomized Clini...
Answer from: Radiation Oncologist at Academic Institution
The plenary on prostate (proton vs photon) - both arms did very well, no clear benefit of protons
Answer from: Radiation Oncologist at Community Practice
The PARTIQoL study being negative was huge - and validates what we saw in our claims-based analyses.